A study in the UK demonstrated significant improvements in HbA1c for users of automated insulin delivery technologies.
This comes on the heels of a UK NHS initiative to provide tens of thousands of children and adults with type 1 diabetes in the country with an artificial pancreas.
The study aimed to assess the efficacy of hybrid closed-loop systems at 12 months. It looked at HbA1c, time in range, hypoglycemia frequency and quality of life measures among children and young people with type 1 diabetes.
Investigators conducted the study between Aug. 1, 2021, and Dec. 10, 2022 across eight pediatric diabetes centers in England. They utilized three automated insulin delivery systems, all fully funded by the NHS:
- Tandem t:slim X2 pump with Control IQ technology in combination with the Dexcom G6 CGM.
- Medtronic MiniMed 780G with Guardian 4.
- Ypsomed YpsoPump with CamDiab CamAPS FX and Dexcom G6.
Get the full story at our sister site, Drug Delivery Business News.